Bayzed Health

Bayzed Health Group Inc. operates as a specialized oncology healthcare group, primarily focusing on the investment in and provision of medical services within the People's Republic of China. Founded in 2017, the company has established a significant presence in the Chinese private healthcare market, which is projected to experience substantial growth. The firm's operational strategy involves a network of hospitals, through which it delivers full-cycle oncology healthcare. This comprehensive service model covers the entire patient journey, from initial screening, diagnosis, and treatment to rehabilitation and hospice care.

The company's business is structured around several core activities: direct hospital operations, hospital management services, and the supply of pharmaceuticals, medical equipment, and consumables. Bayzed Health directly owns six private for-profit hospitals and manages two private not-for-profit hospitals across key regions including Beijing, Tianjin, and the provinces of Shanxi, Anhui, and Henan. This dual approach of ownership and management allows for a flexible expansion strategy. A significant portion of its growth has been fueled by acquisitions, a key component of its strategy to consolidate its position in a competitive market. For the fiscal year 2024, the company reported revenues of approximately $166 million and has since pursued further growth through a public listing.

In June 2025, Bayzed Health Group launched its initial public offering on the Hong Kong Stock Exchange, raising capital to fund further expansion of its oncology services, acquire additional hospitals, enhance its hospital management business, and upgrade IT systems. The company has demonstrated considerable growth in patient volume, with outpatient visits at its owned hospitals increasing more than threefold between 2021 and 2023. This expansion reflects the rising demand for private oncology services in China. Bayzed Health is positioned as the fifth-largest private provider of oncology services in China by revenue, holding a market share of approximately 0.5%.

Keywords: oncology healthcare, China healthcare market, hospital network, cancer treatment, medical services investment, private hospitals, full-cycle oncology care, medical diagnostics, cancer rehabilitation, pharmaceutical supply, medical equipment, hospital management, healthcare acquisitions, Hong Kong Stock Exchange, public healthcare company, Beijing hospitals, cancer screening, tumor diagnosis, inpatient services, outpatient services, healthcare M&A